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Karen S. Anderson is a Professor of Pharmacology and
Molecular Biophysics and Biochemistry. She is involved
in teaching undergraduates and graduate students
about drug discovery and structure-based drug design.
Dr. Anderson's research utilizes mechanistic enzymology
and structure-based drug design. Her work focuses on
understanding how enzymes, playing critical roles in
such diseases as cancer and infectious diseases,
including AIDS, work at a molecular level. She uses that
information to develop new drug therapies. She has
trained over 50 students and postdocs who have gone
on to graduate - and medical schools as well as and
successful careers in academia and industry.
The World Health Organization estimates that in 2018 almost 40 million
people worldwide are infected with HIV. The most recent CDC report
estimates that in the US over 1.2 million people are infected including about
13% who are unaware of their infections. With the development of
antiretroviral therapy (ART), there has been much needed progress over
the past decade. The continual emergence of drug resistance HIV variants
and side effects of life long therapy necessitates the development of new
therapies. Our work has centered upon the viral polymerase molecular
target, HIV reverse transcriptase (RT). We are using mechanistic studies
with computational and structural guidance to design more effective
therapies that have improved therapeutic properties.
